Karuna Therapeutics, Inc.

Bristol Myers Squibb made a $14bn gamble when it agreed to buy Karuna Therapeutics in late 2023 for its drug that was pending US Food and Drug Administration approval at the time of the acquisition. T

It looks as though nothing will come of the takeover talks PureTech Health has held with Nordic Capital Epsilon but there is a compelling argument for taking its ‘hub-and-spoke’ business private in th

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

The US Food and Drug Administration is in the early phases of reconsidering the long-standing class-wide “black box” warning for antipsychotics citing increased mortality in older adults with dementia